CTT PHARMACEUTICAL HOLDINGS, INC. purchased $454 of CTTH
CTT PHARMACEUTICAL HOLDINGS, INC. (CEO) purchased 10,100 shares of CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) at $0.04 on 2026-09-22.
How this was made
The 30-second read
Why it matters
The purchase is a primary disclosure but trivial in scale, offering little actionable insight.
Market read
Limited relevance; small insider buy does not materially affect price or sector.
What to watch
Potential upcoming catalyst not disclosed could make the purchase more material than it appears.
Background
Form 4 filing discloses insider transactions to the SEC; this is the first public report of the purchase.
Ticker impact
CEO purchased 10,100 shares for $454.50 via open-market transaction on 2026-09-22.
Minimal impact; likely no immediate price movement.
The transaction amount is under $1M and represents a tiny fraction of total shares outstanding, limiting market relevance.
Market effects
None; insider activity does not affect the broader pharmaceutical sector.
None; limited to the company.
None; micro‑cap transaction with no global significance.
Counterpoint
If the CEO is buying, the market may undervalue the stock, presenting a potential upside.
Key entities
- CompanyCTT Pharmaceutical Holdings, Inc.
Issuer of the Form 4 filing.
- InsiderCEO (unnamed)
Reported the purchase of 10,100 shares.